Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11997785 | 0.83 | IP6K1 (0.31) | IP6K1 | |
| SCHEMBL264531 | 0.83 | BCHE (0.34) | NT5EHTR1ABCHE | |
| SCHEMBL3365162 | 0.83 | HSPA5 (0.38) | NT5EHTR1A | |
| SCHEMBL12261139 | 0.81 | IP6K1 (0.33) | TACR2LMNANT5EHTR1AIP6K1 | |
| SCHEMBL259615 | 0.81 | RAF1 (0.38) | TACR2NT5EBCHE | |
| SCHEMBL264649 | 0.79 | HTR1A (0.42) | TACR2NT5EHTR1ABCHEACHE | |
| SCHEMBL22579768 | 0.77 | TACR2 (0.43) | TACR2NT5EHTR1ABCHEACHE | |
| SCHEMBL12365715 | 0.75 | HTR1A (0.33) | TACR2LMNANT5EHTR1ABCHE | |
| SCHEMBL12261141 | 0.74 | HTR1A (0.34) | HTR1A | |
| SCHEMBL260030 | 0.74 | NT5E (0.35) | TACR2NT5EBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | TACR2 4788/4885LMNA 4216/4885NT5E 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.